Novartis Pays Arvinas US$150 M Upfront for Prostate Cancer Protein Degrader
By Lucy Haggerty
Pharma Deals Review: Vol 2024 Issue 4 (Table of Contents)
Published: 27 Apr-2024
DOI: 10.3833/pdr.v2024.i4.2871 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Strengthening its commitment to oncology, Novartis has signed a license and asset purchase agreement with Arvinas to develop and commercialise ARV-766 and purchase Arvinas’ preclinical AR-V7 programme...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS